25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Mithra Pharmaceuticals SA
Buy, Hold or Sell?

Let's analyze Mithra together

I guess you are interested in Mithra Pharmaceuticals SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Mithra Pharmaceuticals SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Mithra Pharmaceuticals SA

I send you an email if I find something interesting about Mithra Pharmaceuticals SA.

Quick analysis of Mithra (30 sec.)










What can you expect buying and holding a share of Mithra? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
‚ā¨-1.49
Expected worth in 1 year
‚ā¨-9.48
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨-7.99
Return On Investment
-3,698.6%

For what price can you sell your share?

Current Price per Share
‚ā¨0.22
Expected price per share
‚ā¨0.2155 - ‚ā¨0.22
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Mithra (5 min.)




Live pricePrice per Share (EOD)

‚ā¨0.22

Intrinsic Value Per Share

‚ā¨-8.18 - ‚ā¨15.71

Total Value Per Share

‚ā¨-9.67 - ‚ā¨14.21

2. Growth of Mithra (5 min.)




Is Mithra growing?

Current yearPrevious yearGrowGrow %
How rich?-$111.9m$36.5m-$148.5m-132.6%

How much money is Mithra making?

Current yearPrevious yearGrowGrow %
Making money-$188.1m-$64.6m-$123.4m-65.6%
Net Profit Margin-432.1%-89.0%--

How much money comes from the company's main activities?

3. Financial Health of Mithra (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Mithra? (5 min.)

Welcome investor! Mithra's management wants to use your money to grow the business. In return you get a share of Mithra.

What can you expect buying and holding a share of Mithra?

First you should know what it really means to hold a share of Mithra. And how you can make/lose money.

Speculation

The Price per Share of Mithra is ‚ā¨0.216. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mithra.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mithra, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨-1.49. Based on the TTM, the Book Value Change Per Share is ‚ā¨-2.00 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mithra.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps-2.72-1,260.1%-2.72-1,260.1%-0.97-447.3%-1.50-694.9%-0.90-418.9%
Usd Book Value Change Per Share-2.17-1,002.7%-2.17-1,002.7%0.00-1.1%-0.81-376.4%-0.17-76.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.001.7%
Usd Total Gains Per Share-2.17-1,002.7%-2.17-1,002.7%0.00-1.1%-0.81-376.4%-0.16-75.2%
Usd Price Per Share1.36-1.36-3.69-15.31-13.02-
Price to Earnings Ratio-0.50--0.50--3.82--19.24--31.08-
Price-to-Total Gains Ratio-0.63--0.63--1,489.04--319.17--188.76-
Price to Book Ratio-0.84--0.84-6.76-12.91-9.32-
Price-to-Total Gains Ratio-0.63--0.63--1,489.04--319.17--188.76-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.2342304
Number of shares4269
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-2.17-0.81
Usd Total Gains Per Share-2.17-0.81
Gains per Quarter (4269 shares)-9,245.95-3,471.06
Gains per Year (4269 shares)-36,983.81-13,884.23
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-36984-369940-13884-13894
20-73968-739780-27768-27778
30-110951-1109620-41653-41662
40-147935-1479460-55537-55546
50-184919-1849300-69421-69430
60-221903-2219140-83305-83314
70-258887-2588980-97190-97198
80-295871-2958820-111074-111082
90-332854-3328660-124958-124966
100-369838-3698500-138842-138850

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.012.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%4.06.00.040.0%6.06.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%1.00.09.010.0%2.00.010.016.7%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%4.06.00.040.0%6.06.00.050.0%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Mithra

About Mithra Pharmaceuticals SA

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

Fundamental data was last updated by Penke on 2024-07-07 23:46:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Mithra Pharmaceuticals SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Mithra earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Mithra to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -432.1%¬†means that¬†€-4.32 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mithra Pharmaceuticals SA:

  • The MRQ is -432.1%. The company is making a huge loss. -2
  • The TTM is -432.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-432.1%TTM-432.1%0.0%
TTM-432.1%YOY-89.0%-343.1%
TTM-432.1%5Y-416.8%-15.3%
5Y-416.8%10Y-247.1%-169.7%
1.1.2. Return on Assets

Shows how efficient Mithra is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Mithra to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • -60.5% Return on Assets means that¬†Mithra generated¬†€-0.61 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mithra Pharmaceuticals SA:

  • The MRQ is -60.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -60.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-60.5%TTM-60.5%0.0%
TTM-60.5%YOY-13.5%-47.1%
TTM-60.5%5Y-25.2%-35.3%
5Y-25.2%10Y-19.3%-5.9%
1.1.3. Return on Equity

Shows how efficient Mithra is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Mithra to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • 0.0% Return on Equity means Mithra generated €0.00¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mithra Pharmaceuticals SA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-177.0%+177.0%
TTM-5Y-119.4%+119.4%
5Y-119.4%10Y-75.8%-43.6%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Mithra Pharmaceuticals SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mithra is operating .

  • Measures how much profit Mithra makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Mithra to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -172.6%¬†means the company generated €-1.73 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mithra Pharmaceuticals SA:

  • The MRQ is -172.6%. The company is operating very inefficient. -2
  • The TTM is -172.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-172.6%TTM-172.6%0.0%
TTM-172.6%YOY-49.9%-122.7%
TTM-172.6%5Y-322.0%+149.3%
5Y-322.0%10Y-191.2%-130.7%
1.2.2. Operating Ratio

Measures how efficient Mithra is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 2.73 means that the operating costs are €2.73 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 2.726. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.726. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.726TTM2.7260.000
TTM2.726YOY1.499+1.227
TTM2.7265Y4.220-1.493
5Y4.22010Y3.091+1.129
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Mithra Pharmaceuticals SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mithra is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.90¬†means the company has €0.90 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 0.898. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.898. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.898TTM0.8980.000
TTM0.898YOY1.118-0.220
TTM0.8985Y1.668-0.770
5Y1.66810Y1.994-0.326
1.3.2. Quick Ratio

Measures if Mithra is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Mithra to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.43¬†means the company can pay off €0.43 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 0.433. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.433. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.433TTM0.4330.000
TTM0.433YOY0.675-0.241
TTM0.4335Y1.190-0.756
5Y1.19010Y1.998-0.808
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Mithra Pharmaceuticals SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mithra assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Mithra to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 1.36¬†means that Mithra assets are¬†financed with 136.0% credit (debt) and the remaining percentage (100% - 136.0%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 1.360. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.360. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.360TTM1.3600.000
TTM1.360YOY0.924+0.436
TTM1.3605Y0.898+0.462
5Y0.89810Y0.721+0.178
1.4.2. Debt to Equity Ratio

Measures if Mithra is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Mithra to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 0.0% means that company has €0.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY12.133-12.133
TTM-5Y5.469-5.469
5Y5.46910Y3.386+2.083
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Mithra Pharmaceuticals SA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Mithra generates.

  • Above 15 is considered overpriced but¬†always compare¬†Mithra to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -0.50 means the investor is paying €-0.50¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mithra Pharmaceuticals SA:

  • The EOD is -0.086. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.500. Based on the earnings, the company is expensive. -2
  • The TTM is -0.500. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.086MRQ-0.500+0.414
MRQ-0.500TTM-0.5000.000
TTM-0.500YOY-3.821+3.322
TTM-0.5005Y-19.243+18.743
5Y-19.24310Y-31.076+11.833
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mithra Pharmaceuticals SA:

  • The EOD is -6.836. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -39.690. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -39.690. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.836MRQ-39.690+32.853
MRQ-39.690TTM-39.6900.000
TTM-39.690YOY-2.467-37.222
TTM-39.6905Y-18.921-20.768
5Y-18.92110Y-36.644+17.722
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mithra is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of -0.84 means the investor is paying €-0.84¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Mithra Pharmaceuticals SA:

  • The EOD is -0.145. Based on the equity, the company is expensive. -2
  • The MRQ is -0.839. Based on the equity, the company is expensive. -2
  • The TTM is -0.839. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.145MRQ-0.839+0.695
MRQ-0.839TTM-0.8390.000
TTM-0.839YOY6.763-7.602
TTM-0.8395Y12.909-13.748
5Y12.90910Y9.317+3.592
2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Mithra Pharmaceuticals SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.997-1.9970%-0.002-100%-0.750-62%-0.153-92%
Book Value Per Share---1.494-1.4940%0.503-397%0.863-273%1.124-233%
Current Ratio--0.8980.8980%1.118-20%1.668-46%1.994-55%
Debt To Asset Ratio--1.3601.3600%0.924+47%0.898+51%0.721+89%
Debt To Equity Ratio----0%12.133-100%5.469-100%3.386-100%
Dividend Per Share----0%-0%-0%0.003-100%
Eps---2.510-2.5100%-0.891-64%-1.384-45%-0.834-67%
Free Cash Flow Per Share---0.032-0.0320%-1.380+4268%-1.097+3374%-0.716+2165%
Free Cash Flow To Equity Per Share---0.329-0.3290%-0.069-79%-0.222-33%0.118-378%
Gross Profit Margin--1.0131.0130%1.035-2%1.028-1%1.201-16%
Intrinsic Value_10Y_max--15.707--------
Intrinsic Value_10Y_min---8.177--------
Intrinsic Value_1Y_max---0.223--------
Intrinsic Value_1Y_min---1.038--------
Intrinsic Value_3Y_max--0.700--------
Intrinsic Value_3Y_min---2.948--------
Intrinsic Value_5Y_max--3.274--------
Intrinsic Value_5Y_min---4.656--------
Market Cap14452214.400-500%86681875.96286681875.9620%227823102.000-62%945288974.792-91%803807613.196-89%
Net Profit Margin---4.321-4.3210%-0.890-79%-4.168-4%-2.471-43%
Operating Margin---1.726-1.7260%-0.499-71%-3.220+86%-1.912+11%
Operating Ratio--2.7262.7260%1.499+82%4.220-35%3.091-12%
Pb Ratio-0.145+83%-0.839-0.8390%6.763-112%12.909-107%9.317-109%
Pe Ratio-0.086+83%-0.500-0.5000%-3.821+665%-19.243+3752%-31.076+6120%
Price Per Share0.216-481%1.2541.2540%3.405-63%14.120-91%12.009-90%
Price To Free Cash Flow Ratio-6.836+83%-39.690-39.6900%-2.467-94%-18.921-52%-36.644-8%
Price To Total Gains Ratio-0.108+83%-0.628-0.6280%-1489.040+237062%-319.169+50735%-188.763+29965%
Quick Ratio--0.4330.4330%0.675-36%1.190-64%1.998-78%
Return On Assets---0.605-0.6050%-0.135-78%-0.252-58%-0.193-68%
Return On Equity----0%-1.7700%-1.1940%-0.7580%
Total Gains Per Share---1.997-1.9970%-0.002-100%-0.750-62%-0.150-92%
Usd Book Value---111971890.800-111971890.8000%36530182.800-407%61876948.400-281%81222969.720-238%
Usd Book Value Change Per Share---2.166-2.1660%-0.002-100%-0.813-62%-0.166-92%
Usd Book Value Per Share---1.620-1.6200%0.546-397%0.936-273%1.219-233%
Usd Dividend Per Share----0%-0%-0%0.004-100%
Usd Eps---2.722-2.7220%-0.966-64%-1.501-45%-0.905-67%
Usd Free Cash Flow---2368329.600-2368329.6000%-100132411.600+4128%-79642022.960+3263%-51939181.480+2093%
Usd Free Cash Flow Per Share---0.034-0.0340%-1.497+4268%-1.190+3374%-0.776+2165%
Usd Free Cash Flow To Equity Per Share---0.356-0.3560%-0.075-79%-0.241-33%0.128-378%
Usd Market Cap15671981.295-500%93997826.29393997826.2930%247051371.809-62%1025071364.265-91%871648975.750-89%
Usd Price Per Share0.234-481%1.3601.3600%3.692-63%15.312-91%13.023-90%
Usd Profit---188145568.800-188145568.8000%-64651928.000-66%-101640161.360-46%-63163697.440-66%
Usd Revenue--43544082.00043544082.0000%72651546.800-40%51047045.600-15%41991112.760+4%
Usd Total Gains Per Share---2.166-2.1660%-0.002-100%-0.813-62%-0.162-92%
 EOD+2 -6MRQTTM+0 -0YOY+8 -255Y+10 -2310Y+11 -24

3.2. Fundamental Score

Let's check the fundamental score of Mithra Pharmaceuticals SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.086
Price to Book Ratio (EOD)Between0-1-0.145
Net Profit Margin (MRQ)Greater than0-4.321
Operating Margin (MRQ)Greater than0-1.726
Quick Ratio (MRQ)Greater than10.433
Current Ratio (MRQ)Greater than10.898
Debt to Asset Ratio (MRQ)Less than11.360
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.605
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of Mithra Pharmaceuticals SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.220
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Total Stockholder Equity 163,298-5,561157,737-123,89733,840-15333,687-136,942-103,255
Net Working Capital  43,723124,005167,728-164,1323,59611,83615,432-26,005-10,573



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets286,546
Total Liabilities389,803
Total Stockholder Equity-103,255
 As reported
Total Liabilities 389,803
Total Stockholder Equity+ -103,255
Total Assets = 286,546

Assets

Total Assets286,546
Total Current Assets93,408
Long-term Assets193,138
Total Current Assets
Cash And Cash Equivalents 8,980
Net Receivables 36,092
Inventory 48,289
Other Current Assets 47
Total Current Assets  (as reported)93,408
Total Current Assets  (calculated)93,408
+/-0
Long-term Assets
Property Plant Equipment 51,488
Goodwill 5,233
Intangible Assets 108,713
Long-term Assets Other 10,221
Long-term Assets  (as reported)193,138
Long-term Assets  (calculated)175,655
+/- 17,483

Liabilities & Shareholders' Equity

Total Current Liabilities103,981
Long-term Liabilities285,822
Total Stockholder Equity-103,255
Total Current Liabilities
Short-term Debt 26,703
Accounts payable 59,072
Other Current Liabilities 15,699
Total Current Liabilities  (as reported)103,981
Total Current Liabilities  (calculated)101,474
+/- 2,507
Long-term Liabilities
Long-term Liabilities  (as reported)285,822
Long-term Liabilities  (calculated)0
+/- 285,822
Total Stockholder Equity
Common Stock50,594
Retained Earnings -589,294
Accumulated Other Comprehensive Income 10,586
Other Stockholders Equity 424,859
Total Stockholder Equity (as reported)-103,255
Total Stockholder Equity (calculated)-103,255
+/-0
Other
Cash and Short Term Investments 8,980
Common Stock Shares Outstanding 69,124
Current Deferred Revenue2,507
Liabilities and Stockholders Equity 286,546
Net Debt 196,884
Net Working Capital -10,573
Short Long Term Debt Total 205,864



Balance Sheet

All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-31
> Total Assets 
1,551
2,716
3,050
3,676
5,814
7,451
7,249
13,984
13,543
9,648
11,904
15,697
205,587
172,696
244,712
359,728
397,643
521,985
421,918
442,414
286,546
286,546442,414421,918521,985397,643359,728244,712172,696205,58715,69711,9049,64813,54313,9847,2497,4515,8143,6763,0502,7161,551
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
6,272
8,103
8,180
109,089
57,875
74,212
143,362
91,522
238,475
99,389
145,863
93,408
93,408145,86399,389238,47591,522143,36274,21257,875109,0898,1808,1036,272000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
703
1,561
1,678
7,794
2,150
36,190
118,949
49,720
138,675
32,872
28,285
8,980
8,98028,28532,872138,67549,720118,94936,1902,1507,7941,6781,561703000000000
       Short-term Investments 
598
784
262
974
505
636
1,013
460
158
0
0
0
89,000
43,600
0
0
46
14
-9,312
-2,886
0
0-2,886-9,31214460043,60089,0000001584601,013636505974262784598
       Net Receivables 
137
977
1,767
1,289
2,753
3,617
2,483
8,345
5,734
2,464
3,595
2,687
5,951
3,509
25,429
5,194
25,480
59,957
20,253
62,596
36,092
36,09262,59620,25359,95725,4805,19425,4293,5095,9512,6873,5952,4645,7348,3452,4833,6172,7531,2891,767977137
       Other Current Assets 
0
0
0
0
0
0
0
87
135
693
534
2,052
3,547
4,446
8,452
8,274
3,046
4,449
2,412
4,670
47
474,6702,4124,4493,0468,2748,4524,4463,5472,052534693135870000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
3,376
3,801
6,707
90,021
101,489
143,562
168,431
306,121
283,510
322,529
296,551
193,138
193,138296,551322,529283,510306,121168,431143,562101,48990,0216,7073,8013,376000000000
       Property Plant Equipment 
35
95
164
237
1,051
1,213
1,131
1,054
1,134
1,070
1,457
2,407
3,573
16,961
59,519
84,396
94,037
99,493
107,676
106,251
51,488
51,488106,251107,67699,49394,03784,39659,51916,9613,5732,4071,4571,0701,1341,0541,1311,2131,0512371649535
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
3,814
8,016
5,233
5,233
5,233
5,233
5,233
5,233
5,233
5,233
5,2335,2335,2335,2335,2335,2335,2335,2338,0163,81400000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
214
2,119
198
165
0
0
22,860
0
0
0
0
000022,860001651982,1192140000000000
       Intangible Assets 
650
538
354
735
568
486
416
1,826
1,960
1,887
1,725
2,181
78,234
79,130
78,810
78,802
92,723
94,238
110,187
140,138
108,713
108,713140,138110,18794,23892,72378,80278,81079,13078,2342,1811,7251,8871,9601,826416486568735354538650
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
60
248
-563
-5,345
-12,193
-22,945
-41,628
-370
946
3,990
4,252
10,221
10,2214,2523,990946-370-41,628-22,945-12,193-5,345-56324860000000000
> Total Liabilities 
591
1,665
1,911
2,087
3,836
4,894
6,167
10,391
9,577
7,643
9,416
10,173
78,193
79,681
157,830
208,835
234,345
364,248
388,078
408,727
389,803
389,803408,727388,078364,248234,345208,835157,83079,68178,19310,1739,4167,6439,57710,3916,1674,8943,8362,0871,9111,665591
   > Total Current Liabilities 
293
1,439
1,721
1,516
2,802
3,908
4,541
7,853
7,615
6,315
8,177
8,523
34,540
27,705
52,217
36,109
47,800
70,747
95,793
130,431
103,981
103,981130,43195,79370,74747,80036,10952,21727,70534,5408,5238,1776,3157,6157,8534,5413,9082,8021,5161,7211,439293
       Short-term Debt 
0
0
0
0
0
0
0
0
0
3,597
3,446
23,214
17,854
6,955
15,744
20,253
13,272
18,792
53,128
52,411
26,703
26,70352,41153,12818,79213,27220,25315,7446,95517,85423,2143,4463,597000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
4,685
105
904
6,955
16,237
10,443
6,526
11,477
46,567
47,232
0
047,23246,56711,4776,52610,44316,2376,9559041054,6850000000000
       Accounts payable 
42
1,282
1,270
1,185
1,771
2,816
2,710
3,695
2,136
1,418
2,581
3,544
4,613
9,312
16,141
13,071
19,449
23,325
16,915
31,716
59,072
59,07231,71616,91523,32519,44913,07116,1419,3124,6133,5442,5811,4182,1363,6952,7102,8161,7711,1851,2701,28242
       Other Current Liabilities 
110
58
293
138
413
383
530
2,765
2,667
-1
2,150
-18,235
11,410
11,438
20,332
23,038
14,288
27,371
24,133
44,887
15,699
15,69944,88724,13327,37114,28823,03820,33211,43811,410-18,2352,150-12,6672,76553038341313829358110
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
1,328
1,239
1,650
37,696
48,242
69,189
118,236
186,545
293,501
292,285
278,296
285,822
285,822278,296292,285293,501186,545118,23669,18948,24237,6961,6501,2391,328000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
29,183
39,987
48,736
67,370
64,784
0
0
0
0
000064,78467,37048,73639,98729,183000000000000
       Other Liabilities 
0
0
0
136
0
0
0
19
38
1
0
0
5,957
3,734
2,365
6,484
8,809
8,336
9,251
19,944
0
019,9449,2518,3368,8096,4842,3653,7345,9570013819000136000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,575
3,105
7,441
12,036
19,917
51,969
0
051,96919,91712,0367,4413,1051,57500000000000000
> Total Stockholder Equity
961
1,051
1,140
1,589
1,978
2,557
1,082
3,593
3,966
2,005
2,488
5,524
127,394
93,015
86,882
150,893
163,298
157,737
33,840
33,687
-103,255
-103,25533,68733,840157,737163,298150,89386,88293,015127,3945,5242,4882,0053,9663,5931,0822,5571,9781,5891,1401,051961
   Common Stock
1,919
3,136
3,153
3,376
3,380
3,380
3,480
2,480
2,480
2,480
5,041
3,107
22,613
22,613
25,036
26,925
28,649
31,271
32,250
41,228
50,594
50,59441,22832,25031,27128,64926,92525,03622,61322,6133,1075,0412,4802,4802,4803,4803,3803,3803,3763,1533,1361,919
   Retained Earnings Total Equity000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
-545
-700
-1,036
597
1,305
2,311
1,254
3,424
13,690
-2,545
-19,934
10,586
10,586-19,934-2,54513,6903,4241,2542,3111,305597-1,036-700-545000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
122,830
122,830
148,279
221,587
259,529
0
0
0
0
0000259,529221,587148,279122,830122,830000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
545
700
10,571
122,829
122,830
148,279
223,823
258,898
332,535
340,769
408,647
424,859
424,859408,647340,769332,535258,898223,823148,279122,830122,82910,571700545000000000



Balance Sheet

All numbers in thousands.




Cash Flow

All numbers in thousands.




Income Statement

All numbers in thousands.